Skip to content

MoonLake Immunotherapeutics MLTX Cash Provided by (Used in) Investing Activity, Including Discontinued Operation

Cash Provided by (Used in) Investing Activity, Including Discontinued Operation at other companies

Oruka Therapeutics, Inc. logo
Oruka Therapeutics, Inc.ORKA
-$14.44M-134%

Other financials

Income statement

See full
Operating income-$70.0M-47.5%
Net income-$69.7M-74.5%
EPS (diluted)-$0.98-55.6%

Balance sheet

See full
Cash & equivalents$298.5M+9.9%
Total debt$100.8M+33.3%
Total equity$254.0M-37.7%
Total assets$400.4M-21.7%

Cash flow

See full
Operating cash flow-$66.3M-73.8%
CapEx--100%
Free cash flow-$66.3M-73.6%

Valuation

See full
Market cap$1.49B-45.9%
Enterprise value$1.29B-50.0%

Returns & leverage

See full
Return on equity-77.7%-221pp
Debt / equity0.4×+0.2×
Current ratio8.6×-12.5×

Where this comes from

Reported directly by MoonLake Immunotherapeutics in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.

The official record: MoonLake Immunotherapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about MoonLake Immunotherapeutics's cash provided by (used in) investing activity, including discontinued operation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MoonLake Immunotherapeutics's cash provided by (used in) investing activity, including discontinued operation?
MoonLake Immunotherapeutics (MLTX) reported cash provided by (used in) investing activity, including discontinued operation of $98K in Q1 2026.
How has MoonLake Immunotherapeutics's cash provided by (used in) investing activity, including discontinued operation changed year-over-year?
MoonLake Immunotherapeutics's cash provided by (used in) investing activity, including discontinued operation decreased by 99.8% year-over-year, from $56.25M to $98K.
What does cash provided by (used in) investing activity, including discontinued operation mean?
The total net cash flow resulting from all investing activities, including capital expenditures, acquisitions, and the purchase or sale of securities. It serves as a primary indicator of how much capital the company is reinvesting into its long-term growth and asset base.